Get startedLog in
    Picture of Sensorion SA logo

    ALSEN — Sensorion SA News Story

    0.000.00%
    fr flag iconLast trade - 00:00
    HealthcareHighly SpeculativeSmall CapSucker Stock
    All News

    Brief: Sensorion Receives Positive Opinion For Orphan Drug Designation For OTOF-GT From EMA

    Picture of Sensorion SA logoSensorion SA
    12/09/2022 06:41
    Sept 12 (Reuters) - Sensorion SA  ALSEN.PA :
    * SENSORION RECEIVES POSITIVE OPINION FOR ORPHAN DRUG
DESIGNATION
FOR OTOF-GT FOR THE TREATMENT OF OTOFERLIN GENE-MEDIATED HEARING
LOSS FROM THE EUROPEAN MEDICINE AGENCY
    * SAYS HAS CONTINUED TO PROGRESS WITH PRECLINICAL AND
CLINICAL
DEVELOPMENT PLANS FOR OTOF-GT AND IS ON TRACK TO FILE CLINICAL
TRIAL APPLICATION FOR PROGRAM IN H1 2023

Source text for Eikon:  ID:nBw5yZJ6a 
Further company coverage:  ALSEN.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))

    Recent news on Sensorion SA

    See all news